Enanta Pharmaceuticals (ENTA) Amortizatization of Intangibles (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Amortizatization of Intangibles of -$302000.0 for Q1 2026, down 1410.0% on a QoQ basis from -$20000.0 in Q4 2025, and up 62.99% year-over-year from -$185287.2 in Q1 2025.
Enanta Pharmaceuticals (ENTA) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Amortizatization of Intangibles history runs 15 years deep, the most recent figure standing at -$302000.0 for Q1 2026.
- Quarterly Amortizatization of Intangibles rose 62.99% year-over-year to -$302000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $623000.0 (up 5763.64% YoY) and the FY2025 annual result came in at -$503000.0, down 144.2% from the prior year.
- Amortizatization of Intangibles was -$302000.0 for Q1 2026 at Enanta Pharmaceuticals, down from -$20000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.4 million in Q2 2023 and bottomed at -$816000.0 in Q1 2025.
- A 5-year average of $149647.1 and a median of -$20000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles surged 1778.12% — and 2025, when it tumbled 3164.0%.
- Enanta Pharmaceuticals' Amortizatization of Intangibles stood at $339000.0 in 2022, then tumbled by 180.83% to -$274000.0 in 2023, then tumbled by 130.66% to -$632000.0 in 2024, then jumped by 96.84% to -$20000.0 in 2025, then plunged by 1410.0% to -$302000.0 in 2026.
- Business Quant data shows ENTA's Amortizatization of Intangibles at -$302000.0 in Q1 2026, -$20000.0 in Q4 2025, and $958000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Enanta Pharmaceuticals | 371.42 Mn | 207.65 Mn | - | -302,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -302,000.00 |
| Mar 31, 2026 | -302,000.00 |
| Dec 31, 2025 | -20,000.00 |
| Dec 31, 2025 | -20,000.00 |
| Sep 30, 2025 | 958,000.00 |
| Sep 30, 2025 | 958,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Mar 31, 2025 | -816,000.00 |
| Mar 31, 2025 | -816,000.00 |
| Dec 31, 2024 | -632,000.00 |
| Dec 31, 2024 | -632,000.00 |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 235,000.00 |
| Jun 30, 2024 | 235,000.00 |
| Mar 31, 2024 | -25,000.00 |
| Mar 31, 2024 | -25,000.00 |
| Dec 31, 2023 | -274,000.00 |
| Dec 31, 2023 | -274,000.00 |